CoChat

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer’s Disease

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Based on a multitarget strategy, a series of novel chromanone–1-benzyl-1,2,3,6-tetrahydropyridin hybrids were identified for the potential treatment of Alzheimer’s disease (AD). Biological evaluation demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B). The optimal compound C10 possessed excellent dual AChE/MAO-B inhibition both in terms of potency and equilibrium (AChE: IC 50 = 0.58 ± 0.05 μM; MAO-B: IC 50 = 0.41 ± 0.04 μM). Further molecular modeling and kinetic investigations revealed that compound C10 was a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. In addition, compound C10 exhibited low neurotoxicity and potently inhibited AChE enzymatic activity. Furthermore, compound C10 more effectively protected against mitochondrial dysfunction and oxidation than donepezil, strongly inhibited AChE-induced amyloid aggregation, and moderately reduced glutaraldehyde-induced phosphorylation of tau protein in SH-SY5Y cells. Moreover, compound C10 displayed largely enhanced improvements in cognitive behaviors and spatial memory in a scopolamine-induced AD mice model with better efficacy than donepezil. Overall, the multifunctional profiles of compound C10 suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

Overview

Integrity signals

Registry

Crossref · 10.1021/acschemneuro.2c00520

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Safer D. J., 1971, Biol. Psychiatry, 3, 347

Cited by

See all 19

Metadata

Authors
Li, X., Li, T., Zhan, F., Cheng, F., Lu, L., Zhang, B., Li, J., Hu, Z., Zhou, S., Jia, Y., Allen, S., White, L., Phillips, J., Zhu, Z., Xu, J., & Yao, H.
Affiliations
  • China Pharmaceutical University (CN)
  • University of Nottingham (GB)
  • UCL School of Pharmacy (GB)
Corresponding author
  • Zhu, Zheying
  • Xu, Jinyi
  • Yao, Hequan
Venue
ACS Chemical Neuroscience
Published
2022-11-16
Volume
13
Issue
23
Pages
3488-3501
ISSN
1948-7193 (ISSN-L)
OpenAlex
W4309167078
Cited by
18
References
50
Citations by year
2026: 6 · 2025: 3 · 2024: 4 · 2023: 5
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • China Pharmaceutical University
  • University of Nottingham
  • National Natural Science Foundation of China (81874289)
  • ?Double First-Class" University project (CPU2018GY04)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
chromanone derivatives, Alzheimer's disease, multi-target drugs, acetylcholinesterase inhibition, monoamine oxidase B inhibition, peripheral anionic site, mitochondrial dysfunction, amyloid fibril formation, tau phosphorylation, scopolamine-induced cognitive impairment, spatial memory, neuroprotection, donepezil comparison
MeSH terms
Acetylcholinesterase, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Chromones, Humans, Monoamine Oxidase Inhibitors, Drug Design, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.